Nadia Waheed, MD
Uveitis and Ocular Inflammatory Disease · Boston, MANPI 1245214915
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $220,836 of the $346,225 with a category attached, or 63.8%. 17 manufacturers reported payments, led by Topcon Healthcare, Inc. at 33.1% of the total. Reporting peaked in 2019 at $119,767 and has fallen 53.2% since, to $56,000 in 2025.
Across 148 payments — averaging $2339.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Topcon Healthcare, Inc.$115K
- F. Hoffmann-la Roche AG$52K
- Boehringer Ingelheim International GmbH$48K
- Novartis$42K
- Grifols, S.A.$27K
- Genentech, Inc.$20K
- plus $43K from 11 others
Across 19 payments — averaging $40,390 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$499K
- Topcon Corporation$211K
- Genentech, Inc.$32K
- Boehringer Ingelheim International GmbH$24K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$220,83664%
- Speaking & faculty fees$76,49822%
- Travel & lodging$45,09513%
- Food & beverage$3,7651%
- Education$150%
- Gifts$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Topcon Healthcare, Inc. | 32 | $114,656 |
| F. Hoffmann-la Roche AG | 23 | $51,537 |
| Boehringer Ingelheim International GmbH | 9 | $47,520 |
| Novartis | 24 | $41,581 |
| Grifols, S.A. | 2 | $27,327 |
| Genentech, Inc. | 16 | $20,480 |
| Nidek CO., LTD. | 5 | $13,000 |
| Alcon Research LLC | 5 | $11,044 |
| Topcon Corporation | 13 | $10,892 |
| Nidek Incorporated | 1 | $4,938 |
| Alcon | 5 | $1,407 |
| Samsung Bioepis Co., Ltd. | 1 | $1,000 |
| Carl Zeiss Meditec, Inc. | 6 | $377 |
| Boehringer Ingelheim | 1 | $315 |
| Genentech USA, Inc. | 2 | $83 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Alimera Sciences, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$47,023
- BEOVU$37,698
- Lucentis$15,097
- Mirante$8,500
- OCT TRITON$6,863
- OCT MAESTRO$4,363
- OCT-MAESTRO2$2,500
- CIRRUS HD-OCT$112
- PLEX Elite 9000$112
- Clarus 700$112
How this compares
Too few uveitis and ocular inflammatory disease providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other uveitis and ocular inflammatory disease in Boston
- Caroline BaumalBoston$824K
- Elias ReichelBoston$674K
- Lana RifkinBoston$77K
- Jay DukerBoston$22K
- Andrew TyeBoston$918
- Sarkis SoukiasianBurlington$196
- Arnold KrollMilford$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.